CARDIOLOGY SOLUTIONS

Time to intervention can be a risk: delays to reperfusion correlate with higher rates of mortality and morbidity. Approximately 80 percent of all CVD deaths are due to heart attacks.¹

Time is critical for patients who present with acute chest pain, with or without cardiac history. GE’s Cardiovascular IT and Diagnostic Cardiology solutions can provide insights throughout the cardiology care pathway to help improve clinical decisions and outcomes.

MUSE^™ ECG Management
Helps speed the decision process with measurements and analysis tools to support cardiac care. Read More

Centricity^™ Cardio Enterprise²
Helps bridge the gaps between cardiovascular service lines with a single point of access. Read More

Pre-Hospital Transfer

Rapid transport, ECG monitoring and patient stabilization are critical for patients having an ST-segment elevation myocardial infarction. Nearly half of potentially salvageable myocardium is lost within one hour of the coronary artery being occluded, and nearly 2/3 lost within three hours.³

The ability to send observations and test results wirelessly can be invaluable to attending physicians and interventional lab preparations — potentially enabling fast action upon arrival to aid quality patient outcomes such as door to balloon time.⁴

Pre-hospital ECG
Help reduce time to balloon with 12-lead data from EMS to hospital to verify diagnosis, pre-notify ER staff with wireless transfer. Read More

MAC™ resting ECG carts
with 12SL^™ Analysis
Decision support and predictive outcomes plus improved sensitivity through gender specific interpretation. Read More

Diagnosis

There are many potential causes of chest pain. For patients not sent immediately to the interventional lab for revascularization, guidelines suggest use of biomarkers, clinical history, ECG and non-invasive imaging measurement results, and other factors, to determine TIMI risk score which in turn can guide revascularization decisions.⁵

There are available estimates for sensitivity and specificity for the various non-invasive tests to diagnose the presence of CAD, but other factors are frequently considered such as equipment availability and patient tolerance.⁶

CARESCAPE^™ Monitoring Portfolio
Diagnostic quality of 12SL™ analysis and initial interpretation, along with two-way integration to the MUSE™ cardiology information system for fast, validated access to patient’s 12SL history & serial comparison. Read More

ApexPro CH/FX Telemetry
Analyze ECG leads with EK-Pro algorithm to identify arrhythmias. Read More

Revolution^™ CT & CardioGraphe⁷
Achieve one-beat, whole heart acquisition for imaging or comprehensive cardiac assessment with or without beta blockers at any heart rate.⁸
Read More

Discovery^™ MI
Initial risk assessment through myocardial perfusion and cardiac flow reserve., while diagnostic CT allows complementary CT cardiovascular imaging. Read More

Automated Function Imaging
AFI is a more sensitive method for assessment of LV function than the EF and WM (standard echo methods).^9,10,11 Read More

Intervention

For patients sent for revascularization in the catheterization lab, attempts are made to rapidly access the culprit artery and complete further assessment of coronary tree. Rapid intervention can help minimize time to reperfusion from first medical contact.

Innova IGS 5 or Discovery IGS 7
Helps reduce use of contrast and dose with one of the industry’s highest ratings for Detective Quantum Efficiency (DQE).¹² Read More

PCI ASSIST¹³
Help plan, assess and guide interventional procedures with improved visibility up to 85 percent in moving anatomy. Read More

Patient Follow-Up

Follow-up treatment and rehabilitation strategies typically include non-invasive monitoring of LV function and strain.

Vivid^™ Family Ultrasound
Vivid E95 with cSound performance makes 4D as easy as 2D to quantify left ventricular wall motion. Read More

Automated Function Imaging
AFI global LV strain early after acute myocardial infarction reflects myocardial viability and predicts recovery of LV function at 1-year follow-up.¹⁴ Read More

Discovery^™ NM/CT 670 CZT
Scan as fast as 3-minutes improving workflow and patient experience. Read More

Discovery^™ MI
Initial risk assessment through myocardial perfusion and cardiac flow reserve, while diagnostic CT allows complementary CT cardiovascular imaging. Read More

Acute Coronary Syndrome Sources:

1. https://www.who.int/cardiovascular_diseases/en/
2. Centricity Cardio Enterprise is comprised of Centricity Universal Viewer and Centricity Cardio Workflow.
3. NICE. Myocardial infarction with ST-segment elevation. Clinical Guideline 167, December 2013.
4. Myocardial infarction with ST-segment elevation. Clinical Guideline 167, December 2013.
5. Grech ED. ABC of Interventional Cardiology, Wiley-Blackwell, Oxford 2011.
6. Montalescot G et al European Heart Journal (2013) 34, 2949–3003.
7. CardioGraphe is the only dedicated cardiology CT on the market.
8. 8. GE World Class Cardiac CT PPTX, 2017, slide 26 and https://www.gehealthcare.com/products/computed-tomography/revolution-family/revolution-ct, Smart Cardiac section.
9. Mollema et al., Viability assessment with global left ventricular longitudinal strain predicts recovery of left ventricular function after acute myocardial infarction. Circ Cardiovasc Imaging 2010;3:15-23
10. Stanton et al., Prediction of all-cause mortality from global longitudinal speckle strain: Comparison with ejection fraction and wall motion scoring. Circulation Cardiovasc Imaging 2009;2;356-364
11. Lafitte et al., Impact of impaired myocardial deformations on exercise tolerance and prognosis in patients with asymptomatic aortic stenosis, Eur J Echocardiogr 2009;10;414-419
12. DQE values given are typical at f= 0 cycles/mm with RQA5 conditions as defined by IEC62220-1-3standards.
13. PCI ASSIST refers to features of Innova IGS 520, Innova IGS 530 and Discovery IGS 730.
14. http://www.ncbi.nlm.nih.gov/pubmed?term=Prediction%20of%20all-cause%20mortality%20from%20global%20longitudinal%20speckle%20strain%3A%20 comparison%20with%20ejection%20fraction%20and%20wall%20motion%20scoring Circ Cardiovasc Imaging. 2009 Sep;2(5):356-64. Epub 2009 Jul 21.

Among symptomatic patients with medically treated moderate-to-severe aortic stenosis, mortality from the onset of symptoms is approximately 25 percent at one year and 50 percent at two years.¹ GE Healthcare Cardiology Solutions help you make decisions that matter for your patients, staff and hospital.

Time is critical for AS patients who present with significant cardiac issues. GE’s Cardiovascular IT and Diagnostic Cardiology solutions can provide insights throughout the cardiology care pathway to help improve clinical decisions and outcomes.

MUSE^™ ECG Management
Helps speed the decision process with measurements and analysis tools to support cardiac care. Read More

Centricity^™ Cardio Enterprise²
Helps bridge the gaps between cardiovascular service lines with a single point of access. Read More

Early Detection

Due to the high mortality rates by the time patients are symptomatic, it is important to identify patients at risk, even when they are asymptomatic. Echocardiography can identify issues or abnormalities related to Aortic Valve structure and function.³

Vivid^™ E95
Automated Ejection Fraction and LV wall motion quantification. Read More

MAC™ resting ECG carts
with 12SL^™ Analysis
Decision support and predictive outcomes plus improved sensitivity through gender specific interpretation. Read More

Diagnosis

Diagnosis involves assessment of valve morphology, amount of stenosis or insufficiency, LV function, LV hypertrophy, and severity of symptoms. For patients with Aortic Stenosis, there are surgical and catheterization treatment options in addition to medical or palliative care. A risk calculator is typically used to quantify the risk and make a treatment decision.

SIGNA^™ Works CV Imaging & Analysis Tools
One non-invasive CMR exam to assess cardiac morphology, function, flow, tissue viability and coronary anatomy without ionizing radiation. Read More

Vivid^™ E95
Semi-automated 3D valve assessment. Read More

Pre-Procedure Planning

For patients choosing a transcatheter replacement, non-invasive cardiovascular imaging, such as Ultrasound, CT, and MR are typically used to assess anatomy to plan the access site and size the valve.

Vivid^™ 4D
4D acquisition, navigation and quantification to enhance procedure planning. Read More

Revolution^™ CT & CardioGraphe³
Achieve one-beat, whole heart acquisition for imaging or comprehensive cardiac assessment with or without beta blockers at any heart rate.⁴ Read More

SIGNA^™ Works CV Imaging & Analysis Tools
One non-invasive CMR exam to assess cardiac morphology, function, flow, tissue viability and coronary anatomy without ionizing radiation. Read More

AW TAVI Analysis
Integrated cardiology application for sizing, planning and visualization.  Read More

Intervention

During the transcatheter aortic valve replacement, steps are taken to ensure the most effective result, including valve sizing, position, and function are optimal.

Discovery^™ IGS 7 OR
High-quality imaging and work-place freedom for the Hybrid OR. Read More

Valve ASSIST 2
Interventional imaging software to plan, guide and assess valve placement. Read More

CARESCAPE^™ Monitoring Portfolio
Diagnostic quality of 12SL^™ analysis and initial interpretation, along with two-way integration to the MUSE^™ cardiology information system for fast, validated access to patient’s 12SL history & serial comparison. Read More

Patient Follow-Up

After the procedure, care is taken to ensure functionality of the valve typically using non-invasive imaging and ECG.

Vivid^™ E95 and EchoPac^™ Software Only
Perform post-processing offline—even multi-dimensional analyses—on images that retain the same excellent quality as those originally acquired and viewed on the ultrasound system. Read More

MAC™ resting ECG carts
with 12SL^™ Analysis
Decision support and predictive outcomes plus improved sensitivity through gender specific interpretation.  Read More

SIGNA^™ Works CV Imaging & Analysis Tools
One non-invasive CMR exam to assess cardiac morphology, function, flow, tissue viability and coronary anatomy without ionizing radiation. Read More

Revolution^™ CT & CardioGraphe³ Achieve one-beat, whole heart acquisition for imaging or comprehensive cardiac assessment with or without beta blockers at any heart rate.⁴ Read More

Aortic Stenosis Sources:

1. https://emedicine.medscape.com/article/150638-overview
2. Centricity Cardio Enterprise is comprised of Centricity Universal Viewer and Centricity Cardio Workflow.
3. CardioGraphe is the only dedicated cardiology CT on the market.
4. GE World Class Cardiac CT PPTX, 2017, slide 26 and https://www.gehealthcare.com/products/computed-tomography/revolution-family/revolution-ct, Smart Cardiac section.
5. Valve ASSIST 2 is a commercial package which includes TAVI Analysis + HeartVision 2 and requires AW workstation with Volume Viewer, Volume Viewer Interventional. These applications are sold separately

Managing risk factors and follow up for patients with Stable Ischemic Heart Disease is critical. GE’s Cardiovascular IT and Diagnostic Cardiology solutions can provide insights throughout the cardiology care pathway to help improve clinical decisions and outcomes.

Early detection and management including counseling, and medical therapy are important for patients with cardiovascular disease or who are at a high risk, including those with risk factors such as hypertension, diabetes, and high cholesterol.¹

MUSE^™ ECG Management
Helps speed the decision process with measurements and analysis tools to support cardiac care. Read More

Centricity^™ Cardio Enterprise²
Helps bridge the gaps between cardiovascular service lines with a single point of access. Read More

Diagnosis & Risk Stratification

Non-invasive methods for observing response to guideline-directed therapy can be employed, two examples of these methods are 12 SL ECG interpretation and stress imaging. Additionally, if the patient is not responsive to therapy, CT, MR or Nuclear studies may help show functional degradation which might necessitate a follow on intervention such as PCI or CABG.

MAC™ resting ECG carts
with 12SL^™ Analysis
Decision support and predictive outcomes plus improved sensitivity through gender specific interpretation. Read More

SIGNA™ Works CV Imaging & Analysis Tools
One non-invasive CMR exam to assess cardiac morphology, function, flow, tissue viability and coronary anatomy without ionizing radiation. Read More

Vivid^™ E95
Provides Doppler measurement results for the most common parameters, with minimal guidance. Read More

Revolution^™ CT & CardioGraphe³
Achieve one-beat, whole heart acquisition for imaging or comprehensive cardiac assessment with or without beta blockers at any heart rate.⁴
 Read More

Discovery^™ NM530c
Provides scans as fast as three minutes and the flexibility to choose between dose reduction, faster acquisitions or improved statistics. Read More

Case Stress ECG
Helps quickly and easily assess cardiac functions during exercise with this stand-alone, highly scalable testing solution.
 Read More

Intervention

Successful PCI of the stenotic lesions involves planning, guidance, and assessment of the culprit lesion and assessment of the remainder of the coronary tree.

Innova IGS 5⁵
Helps reduce use of contrast and dose with one of the industry’s highest ratings for Detective Quantum Efficiency (DQE).
 Read More

PCI ASSIST⁶
Help plan, assess and guide interventional procedures with improved visibility up to 85 percent in moving anatomy.
 Read More

CARESCAPE ^™ Monitoring Portfolio
Diagnostic quality of 12SL^™ analysis and initial interpretation, along with two-way integration to the MUSE^™ cardiology information system for fast, validated access to patient’s 12SL history & serial comparison. Read More

Patient Follow-Up and Monitoring

Follow-up treatment and rehabilitation strategy can include behavior modification and medical therapy in addition to monitoring cardiac function non-invasively using ALARA principles.

MAC™ resting ECG carts
with 12SL^™ Analysis
Decision support and predictive outcomes plus improved sensitivity through gender specific interpretation. Read More

Case Stress ECG
Helps quickly and easily assess cardiac functions during exercise with this stand-alone, highly scalable testing solution. Read More

Vivid^™ Family Ultrasound
Vivid E95 with cSound performance makes 4D as easy as 2D to quantify left ventricular wall motion. Read More

SIGNA^™ Works CV Imaging & Analysis Tools
One non-invasive CMR exam to assess cardiac morphology, function, flow, tissue viability and coronary anatomy without ionizing radiation.  Read More

Revolution^™ CT & CardioGraphe³
Achieve one-beat, whole heart acquisition for imaging or comprehensive cardiac assessment with or without beta blockers at any heart rate.⁴
 Read More

Discovery^™ NM530c
Provides scans as fast as three minutes and the flexibility to choose between dose reduction, faster acquisitions or improved statistics. Read More

Stable Ischemic Heart Disease Sources:

1. https://www.who.int/en/news-room/fact- sheets/detail/cardiovascular-diseases-(cvds)
2. Centricity Cardio Enterprise is comprised of Centricity Universal Viewer and Centricity Cardio Workflow
3. CardioGraphe is the only dedicated cardiology CT on the market.
4. GE World Class Cardiac CT PPTX, 2017, slide 26 and https://www.gehealthcare.com/products/computed-tomography/revolution-family/revolution-ct, Smart Cardiac section.
5. This presentation refers to Innova IGS 520.
6. PCI ASSIST refers to features of Innova IGS 520, Innova IGS 530 and Discovery IGS 730.

Heart Failure cost is 2-3 percent of the total health-care expenditures in high-income countries, and costs are projected to increase 200 percent in next 20 years world-wide. Current cost in the U.S. is $30.7 billion dollars.¹ Congestive heart failure affects people of all ages, from children and young adults to the middle-aged and the elderly.

Time is critical for Heart Failure patients who present with cardiac issues. GE’s Cardiovascular IT and Diagnostic Cardiology solutions can provide insights throughout the cardiology care pathway to help improve clinical decisions and outcomes.

MUSE^™ ECG Management
Helps speed the decision process with measurements and analysis tools to support cardiac care. Read More

Centricity^™ Cardio Enterprise²
Helps bridge the gaps between cardiovascular service lines with a single point of access. Read More

Early Detection

About half of people who develop heart failure die within five years of diagnosis.³ Important risk factors include HTN, DM, Metabolic Syndrome, and Coronary Artery Disease, but there are many other conditions that put patients at risk. Early identification and treatment of comorbidities can delay the onset of Heart Failure.⁴

Vscan^™ Extend
Bring ultrasound care into every setting in any environment.⁵ Read More

Diagnosis and Risk Assessment

Diagnosis typically involves assessment for ECG abnormality and assessment of cardiac structure, function and possible cause. Guidelines suggest use of echocardiography due to its widespread availability, but other non-invasive imaging modalities can be used. In certain cases, invasive monitoring provides useful information for patients with persistent symptoms. Biomarkers provide helpful information about progression of disease. ⁴

MAC™ resting ECG carts
with 12SL^™ Analysis
Decision support and predictive outcomes plus improved sensitivity through gender specific interpretation. Read More

CARESCAPE^™ Monitoring Portfolio
Diagnostic quality of 12SL™ analysis and initial interpretation, along with two-way integration to the MUSE™ cardiology information system for fast, validated access to patient’s 12SL history & serial comparison. Read More

ApexPro CH/FX Telemetry Analyze ECG leads with EK-Pro algorithm to identify arrhythmias.
Read More

Discovery^™ MI
Initial risk assessment through myocardial perfusion and cardiac flow reserve., while diagnostic CT allows complementary CT cardiovascular imaging.
Read More

SIGNA^™ Works CV Imaging & Analysis Tools
One non-invasive CMR exam to assess cardiac morphology, function, flow, tissue viability and coronary anatomy without ionizing radiation. Read More

Vivid^™ Family Cardiac Ultrasound with Auto EF
Assess left ventricular function and cardiac performance with clarity, improving clinical confidence.  Read More

Treatment and Intervention

Guidelines suggest lifestyle modifications, and use of specific medical therapies, such as ACE inhibitors and beta blockers. For certain patients not responding to medical therapies, guidelines suggest use of ICD or CRT. Revascularization and valve repair are used in certain stages of HF.⁴

Innova IGS 5⁶
Enabling device implantation through enhanced visualization, workflow integration and lower dose by design. Read More

Patient Follow-Up and Monitoring

Guidelines recommend regular follow up to assess severity and extent of left ventricular dysfunction, and development of a follow-up treatment strategy, including monitoring, to prevent acute decompensation and re-admission.⁴

GE Healthcare & Preventice Solutions
Providing in-hospital ECG, long-term Holter, Cardiac Event Monitoring (CEM) & Mobile Cardiac Telemetry (MCT) results into a single portal utilizing MUSE.
Read More

Discovery^™ MI
Initial risk assessment through myocardial perfusion and cardiac flow reserve, while diagnostic CT allows complementary CT cardiovascular imaging.
Read More

SIGNA^™ Works CV Imaging & Analysis Tools
One non-invasive CMR exam to assess cardiac morphology, function, flow, tissue viability and coronary anatomy without ionizing radiation. Read More

Heart Failure Sources:

1. https://www.escardio.org/static_file/Escardio/Subspecialty/HFA/WHFA-whitepaper-15-May-14.pdf
2. Centricity Cardio Enterprise is comprised of Centricity Universal Viewer and Centricity Cardio Workflow
3. Mozzafarian D, Benjamin EJ, Go AS, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360.
4. 2013 ACC guidelines Yancy et al. JACC Vol. 62, No. 16, 2013 2013 ACCF/AHA Heart Failure Guideline: Full Text October 15, 2013:e147–239
5. The device has been verified for limited use outside of professional healthcare facilities during transport. Use is restricted to environmental properties described in the user manual, please contact your GEHealthcare sales representative for detailed information.
6. This presentation refers to Innova IGS 520.